Myungmoon to conduct bioequivalence testing on generic Tamiflu

Published: 2009-10-09 06:56:00

Updated: 2009-10-09 06:56:00

Myungmoon Pham is waiting for approval to conduct bioequivalence test of their generic version of Tamiflu, according to the Korea Food and Drug Administration.

Chong Kun Dang Pharmaceutical and SK Chemicals have received the green light to conduct a bioequivalence test to prove the therapeutic...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK